Business Context and Reporting Period
This Form 8-K Current Report, filed on September 27, 2016, by CorMedix Inc., discloses the appointment of a new Chief Executive Officer (CEO) and the departure of the interim CEO. The report details the terms of the new employment agreement effective October 3, 2016.
Key Financial Metrics and Compensation
The filing does not provide revenue, profit, cash flow, or liquidity metrics. It focuses exclusively on executive compensation arrangements:
- Base Salary: $375,000 annually for the new CEO, Khoso Baluch.
- Annual Bonus: Up to 80% of base salary, contingent on company and personal objectives.
- Stock Options: Grant of 1,850,000 options.
- 1,250,000 options vest in four equal annual installments.
- 300,000 options vest upon achievement of performance milestones (forfeited if not met within 4 years).
- 300,000 options vest upon achievement of a specified average closing stock price (forfeited if not met by Dec 31, 2018).
- Relocation: Up to $75,000 for relocation expenses.
- Severance (Termination without Cause/Good Reason): 12 months of base salary and benefits, prorated bonus, COBRA premium coverage, and acceleration of vesting for options scheduled to vest by the next anniversary.
- Severance (Change in Control): 12 months of base salary and full bonus, COBRA premium coverage, and full acceleration of all unvested restricted shares and options.
Material Changes
The primary material change is the leadership transition:
- Appointment: Khoso Baluch appointed as CEO and to the Board of Directors, effective October 3, 2016.
- Departure: Randy Milby, who served as Interim CEO, will resign from that role and the Board of Directors effective October 2, 2016.
- Compensation Structure: Implementation of a new executive compensation package including significant equity incentives tied to stock price and performance milestones.
Outlook, Risks, and Contingencies
Management Commentary: The company conducted a formal search for a CEO to lead the organization. Mr. Baluch brings extensive experience from UCB and Eli Lilly in general management, business development, and market access.
Risks and Contingencies:
- Equity Forfeiture: A significant portion of the new CEO's equity grant (600,000 options) is contingent on specific performance milestones and stock price targets. Failure to meet these by specified dates results in forfeiture.
- Non-Compete: Mr. Baluch is restricted from engaging in businesses involving preventive anti-infective products competing with Neutrolin or taurolidine for 12 months post-employment.
- Severance Conditions: Enhanced severance benefits are conditioned upon the execution of a release of claims against the company.
Investor Verification Checklist
- Verify the exact vesting schedule and specific performance milestones for the 600,000 contingent stock options granted to Mr. Baluch.
- Confirm the total number of outstanding shares and the potential dilution impact of the 1,850,000 new options.
- Review the definition of "Change in Control" in the full employment agreement (Exhibit 10.1) to understand the trigger for full bonus and equity acceleration.
- Check the company's cash position to assess the ability to fund the $375,000 salary, potential bonuses, and severance obligations.
- Monitor the transition timeline to ensure Mr. Milby's departure and Mr. Baluch's start date align with the October 2016 dates specified.